Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
, x4 A3 n7 I A9 F* T7 @: YNOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 ( F& Y1 A8 p { J9 j4 x, P
+ Author Affiliations- ~9 w/ s6 Z: G% P9 w) O
: F& w) N |7 U; F
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
, Y. Y( ]2 i% C' M* K! I$ p+ L2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan + K% S+ h9 r9 j" ^3 ^
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
4 X6 H# B/ }8 |, c8 S+ ]; P4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan ) }, y+ p+ | {
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
3 i i- Q4 B+ ~6 z9 A6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan 4 e/ A0 \4 K7 c5 D. _4 n2 R; ` o
7Kinki University School of Medicine, Osaka 589-8511, Japan ' _7 K+ N0 z+ C1 U! o6 d
8Izumi Municipal Hospital, Osaka 594-0071, Japan $ u; `! w9 F3 l
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
1 k g; M, F& w$ {/ KCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp * Q4 v! `* U, y( c8 _
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. . L: e. o9 q& V" i. L2 @/ r
. Y" H' i. O8 C" m
|